Nonlymphomatous hepatobiliary masses in cats: 41 cases (1972 to 1991).
The medical and necropsy records of 41 cats diagnosed with nonlymphomatous hepatobiliary (NLHB) masses, including neoplasia and cysts, were reviewed. Overall, benign masses (n = 27) were more common than malignant ones (n = 14). The single most common malignancy was cholangiocellular carcinoma. The median age at diagnosis was significantly lower (P < .01) for cats with malignant rather than benign disease. Clinical signs associated with hepatobiliary neoplasia were usually vague and included lethargy, vomiting, and anorexia, often present for at least 2 weeks before presentation. Benign masses were an incidental finding in significantly more (P < .01) of the cases than were malignant masses. Median values for alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin were significantly higher (P < .05) in cats with malignant versus benign masses. The prognosis for malignant disease was poor, with 86% of the cats dying or being euthanatized during hospitalization. Cats with benign disease that underwent exploratory celiotomy were more likely to recover and warranted a more favorable prognosis than cats with malignant tumors. Factors associated with malignancy included age at presentation, presence of clinical signs at presentation, and specific serum chemistry changes.
Department of Clinical Sciences, New York State College of Veterinary Medicine, Cornell University, Ithaca.
H J
HJ
Lawrence
H N
HN
Erb
H J
HJ
Harvey
D002759:Adenoma, Bile Duct / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D018248:Adenoma, Liver Cell / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001660:Biliary Tract Diseases / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary*; D001661:Biliary Tract Neoplasms / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary*; D001663:Bilirubin / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D002371:Cat Diseases / Q000453:epidemiology* / Q000601:surgery; D002415:Cats; D018281:Cholangiocarcinoma / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D002784:Cholesterol / Q000097:blood; D003560:Cysts / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D005260:Female; D005354:Fibrosarcoma / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D006394:Hemangiosarcoma / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary; D008107:Liver Diseases / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary*; D008113:Liver Neoplasms / Q000453:epidemiology / Q000601:surgery / Q000662:veterinary*; D008297:Male; D009518:New York / Q000453:epidemiology; D011379:Prognosis; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D002784:Cholesterol; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin